Axsome Therapeutics, Inc. 8-K

What Happened
On April 1, 2026, Axsome Therapeutics, Inc. (NASDAQ: AXSM) filed an 8-K and issued a press release announcing the acquisition of balipodect, a selective PDE10A inhibitor intended for the treatment of schizophrenia and other neuropsychiatric conditions. The press release is included as Exhibit 99.1 to the 8-K. The report was signed by President and CEO Herriot Tabuteau, M.D., dated April 1, 2026.

Key Details

• Acquisition announced April 1, 2026; press release titled “Axsome Therapeutics Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and other Neuropsychiatric Conditions.”
• Balipodect is described as a selective PDE10A inhibitor targeting schizophrenia and other neuropsychiatric disorders.
• The 8-K includes the press release as Exhibit 99.1; no purchase price or financial terms were disclosed in the filing.
• Filing signed by CEO Herriot Tabuteau on April 1, 2026.

Why It Matters
This acquisition adds a development-stage compound focused on schizophrenia to Axsome’s pipeline, which could broaden the company’s neuropsychiatry portfolio and R&D focus. Because the 8-K does not disclose financial terms or clinical status details, investors should watch for follow-up disclosures (e.g., financial impact, clinical data, regulatory plans) that would clarify the deal’s significance to Axsome’s valuation and near-term milestones.